Full FDA Approvals in Breast Cancer and Lung Cancer, Priority Reviews in ALL, and More

Brielle Urciuoli reports on full FDA approvals in breast cancer and non—small cell lung cancer, priority reviews in acute lymphoblastic leukemia, an ODAC recommendation for hematologic malignancies, a biologics license application submitted in non–Hodgkin lymphoma, a new drug application accepted in graft-versus-host disease, promising phase III results and a European approval in lung cancer.